Company Profile of Cipla pharmaceuticals limited

LOGO

COMPANY PROFILE
Khwaja Abdul Hamied, the founder of Cipla, was born on

October 31, 1898.

In 1935, he set up The Chemical, Industrial & Pharmaceutical

Laboratories, which came to be popularly known as Cipla.

On August 17, 1935, Cipla was registered as a public limited

company with an authorized capital of Rs. 6 lakhs.

Cipla was officially opened on September 22, 1937 when the

first products were ready for the market.

July 4, 1939 was a red-letter day for Cipla, when the Father of

the Nation, Mahatma Gandhi, honoured the factory with a visit.

BOARD OF DIRECTORS
Founder -Dr. K.A. Hamied (1898-1972) Chairman & Managing Director - Dr. Y.K. Hamied Joint Managing Directors - Mr. M.K. Hamied, Mr. Amar

Lulla. Whole time Director - Mr. S. Radhakrishnan. Non-Executive Directors - Mr. V.C. Kotwal, Dr. H.R. Manchanda, Mr. Ranjan Pai, Mr. M.R. Raghavan, Mr. Ramesh Shroff, Mr. Pankaj Patel.

Milestones
1935- Dr. K A Hamied sets up "The Chemical, Industrial

and Pharmaceutical Laboratories Ltd." in a rented bungalow, at Bombay Central. 1941- As the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort. 1952- Sets up first research division. 1960- Starts operations at second plant at Vikhroli, Mumbai, with special emphasis on natural products. 1982- Fourth factory begins operations at Patalganga, Maharashtra. 1984- Develops anti-cancer drugs, vinblastine and vincristine in collaboration with the National Chemical Laboratory, Pune. Wins Sir P. C. Ray Award for developing inhouse technology for indigenous manufacture of a number of basic drugs. 1985- US FDA approves Cipla's bulk drug manufacturing facilities. 1988- Cipla wins National Award for Successful Commercialization of Publicly Funded R&D. 1991- Launches etoposide, a breakthrough in cancer chemotherapy, in association with Indian Institute of Chemical Technology. The company pioneers the manufacture of the antiretroviral drug, zidovudine, in technological collaboration with Indian Institute of Chemical Technology, Hyderabad. 1994- Cipla's fifth factory begins commercial production at Kurkumbh, Maharashtra.

 1997- Launches transparent Rotahaler, the world's first dry

powder inhaler device now patented by Cipla in India and abroad. The palliative cancer care Centre set up by the Cipla Foundation, begins offering free services at Warje, near Pune.
1998- Launches lamivudine, becoming one of the few

companies in the world to offer all three component drugs of retroviral combination therapy (zidovudine and stavudine already launched.
1999- Launches Nevirapine, antiretroviral drug, to prevent

the transmission of AIDS from mother to child.

2000- Became the first company, outside the USA and

Europe to launch CFC-free inhalers.

2002- Four state-of-the-art manufacturing facilities set up in

Goa in a record time of less than twelve months.

2003- Launches TIOVA (Tiotropium bromide), a novel

inhaled, long-acting anticholinergic bronchodilator as a oncedaily maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).
Commissioned second phase of manufacturing operations at

Goa.

 2005- Set-up state-of-the-art facility for manufacture of

formulations at Baddi, Himachal Pradesh.

2007- Set-up state-of-the-art facility for manufacture of

formulations at Sikkim.

2010- Set up state-of-the-art facility for manufacture of

formulations at Indore.

AWARDS AND ACHIEVEMENTS

Ciplas Director Received Padma Bushan Award In 2005

i.e. Dr.Y.K.Hamied. Cipla launches medicinal aerosols for asthma in 1976. Wins Chemexcil Award for Excellence for exports in 1980. Cipla wins National Award for Successful Commercialization of Publicly Funded R&D in 1988. Set-up state-of-the-art facility for manufacture of formulations at Sikkim in 2007.

Code of Conduct The following code of conduct has been approved by

the Board of Directors and is applicable to the Directors and Senior Management of the Company

1. Ethical conduct- Directors and senior management employees shall deal on behalf of the Company with professionalism, honesty, integrity high moral and ethical standards. 2. Conflict of interest- They shall not engage in any business, relationship or activity, which might detrimentally conflict with the interest of the Company. 3. Transparency- All directors and senior management employees of the Company shall ensure that their actions in the conduct of business are totally transparent except where the needs of business security dictate otherwise.. 4. Legal compliance-Shall at all times ensure compliance with all the relevant laws and regulations affecting operations of the Company. 5. Rightful use of companys assets- All the assets of the Company both tangible and intangible shall be employed for the purpose of conducting the business for which they are duly authorized. 6. Cost consciousness- Should strive for optimum utilization of available resources, shall exercise care to ensure that costs are reasonable and there is no wastage. 7. Confidential information- Any confidential information gained in their official capacity is not utilized for personal profit or for the advantage of any other person.. 8. Relationships with Suppliers and Customers Shall neither receive nor offer or make, directly and indirectly, any illegal payments, remuneration, gifts, donations or comparable benefits for the conduct of business. 9. Interaction with Media Shall not engage with any member of press and media in matters concerning the Company.

10. Safety and Environment- Shall follow all prescribed safety and environment-related norms.

PRODUCTS
Alzheimer`s Dementia Amoebicides/Antiprotozoals Anabolic Steroids Analgesics/Antipyretics Anesthetic Agent Antacids/Antiflatulents Anthelmintics Anti-Arthritis Anti-Inflammatory Drugs Anti-TB Drugs Antiacne/Antipsoriatic Drugs Antiallergic Drugs

Antibiotics/Antibacterials

Anticancer Drugs

COMPETITORS
RANBAXY NICHOLAS PIRAMAL SUN PHARMA NOVARTIS PFIZER REDDY LABS

Analyzing Strengths and Weaknesses

Areas of Strength:
Customer loyalty Dominant market share position Effectiveness of advertising Quality sales force Make and sell products of highest quality High integrity as a company.

Analyzing Strengths and Weaknesses

Areas of Strength: Excellence in product design and/or performance Low-cost, high operating skill Leadership in product innovation Efficiency in customer service Personal relationships with customers Effectiveness in sales promotion Merchandising efficiency

Analyzing Strengths and Weaknesses

Areas of weaknesses:
Inadequate definition of customer for product/market

development Ambiguous service policies Too many levels of reporting in the organizational setup Overlapping channels Lack of top management involvement in new product development Lack of quantitative goals

Cipla Care
Dr. K. A. Hamied Institute Cipla Cancer Palliative Care and Training Centre

THANK YOU
Presentation Done By-

Jasingfa Buragohain, Partha Ganguly, Sudeshna Ghosh Sarkar, Abhijit Kundu & Biswajit Santra.